Skip to main content

JOHNSON & JOHNSON

corporate_fare Company Profile

JOHNSON & JOHNSON

JNJ·NYSE·Life Sciences·CIK 0000200406

Johnson & Johnson is a global healthcare company with approximately 138,200 employees worldwide. The company focuses on the research, development, manufacturing, and sale of a wide range of products primarily related to human health and well-being. Incorporated in New Jersey in 1887, Johnson & Johnson operates through its subsidiaries in virtually all countries globally. The company is structured into two main business segments: Innovative Medicine and MedTech. The Innovative Medicine segment concentrates on several therapeutic areas. These include Oncology, addressing conditions such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer. In Immunology, the focus is on rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. Neuroscience covers mood disorders, neurodegenerative disorders, and schizophrenia. The segment also addresses Pulmonary Hypertension, specifically Pulmonary Arterial Hypertension, and Infectious Diseases like HIV/AIDS. Additionally, it covers Cardiovascular and Metabolism, including thrombosis, diabetes, and macular degeneration. Products within the Innovative Medicine segment are distributed for prescription use directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals.

JOHNSON & JOHNSON (NYSE:JNJ) is a publicly traded company in the Life Sciences sector. Wiseek monitors JNJ SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • U.S. Court Disqualifies Key Law Firm from J&J Talc Litigation, Weakening Plaintiffs' Case
  • European Commission Approves J&J's AKEEGA for BRCA1/2-Mutated Prostate Cancer
  • FDA Approves J&J's Tecvayli for Myeloma; Company Settles Antitrust Claims
  • J&J's Nipocalimab Receives FDA Fast Track Designation for Systemic Lupus Erythematosus
  • Johnson & Johnson Reports Strong 2025 Earnings, Reverses $7B Talc Reserve, and Announces Orthopaedics Business Separation

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$94.19B
Net Income
$26.8B
Diluted EPS
$11.03
Op. Cash Flow
$24.53B
Free Cash Flow
$19.7B
Gross Profit
$63.94B
Cash & Equivalents
$19.71B
Total Debt
$41.44B
Debt / Equity
0.51×
Net Margin
28.5%
Shares Outstanding
2.41B sh
Source: 10-K · filed 2026-02-11 · accession 0000200406-26-000016
$239.55
52-week range · as of 2026-04-22 $146.12 – $251.71
Market cap
$576.65B
Volume
2.7M (0.4× avg)
3-mo avg 7.5M
Live data · 2026-06-12 17:10 UTC · Market open

show_chartPrice Chart

Loading chart...

feed JNJ - Filings & News (Page 2)

JNJ
Mar 27, 2026, 3:04 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $241.13
Real-time Price: $239.55 info
Change: -$1.58 (-0.66%) info
Market Cap: $576.649B info
JNJ
Mar 09, 2026, 1:07 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $242.70
Real-time Price: $239.55 info
Change: -$3.15 (-1%) info
Market Cap: $576.649B info
JNJ
Mar 06, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $239.28
Real-time Price: $239.55 info
Change: +$0.270 (+0.11%) info
Market Cap: $576.649B info
JNJ
Mar 03, 2026, 8:11 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $246.05
Real-time Price: $239.55 info
Change: -$6.50 (-3%) info
Market Cap: $576.649B info
JNJ
Feb 11, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $241.13
Real-time Price: $239.55 info
Change: -$1.58 (-0.66%) info
Market Cap: $576.649B info
JNJ
Jan 21, 2026, 7:46 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $212.95
Real-time Price: $239.55 info
Change: +$26.60 (+12%) info
Market Cap: $576.649B info